Exact Sciences Corp
NASDAQ:EXAS

Watchlist Manager
Exact Sciences Corp Logo
Exact Sciences Corp
NASDAQ:EXAS
Watchlist
Price: 58.4 USD -1.68%
Market Cap: 10.8B USD
Have any thoughts about
Exact Sciences Corp?
Write Note

Net Margin
Exact Sciences Corp

-8%
Current
-24%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-8%
=
Net Income
-214m
/
Revenue
2.7B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Exact Sciences Corp
NASDAQ:EXAS
10.8B USD
-8%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
310.2B USD
9%
US
Amgen Inc
NASDAQ:AMGN
142B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
134.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country US
Market Cap 10.8B USD
Net Margin
-8%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.2B USD
Net Margin
9%
Country US
Market Cap 142B USD
Net Margin
13%
Country US
Market Cap 115B USD
Net Margin
0%
Country US
Market Cap 101.6B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78.5B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Exact Sciences Corp
Glance View

Market Cap
10.8B USD
Industry
Biotechnology
Economic Moat
None

Exact Sciences Corp. has crafted a compelling narrative in the realm of molecular diagnostics, primarily revolutionizing the way cancer is detected and managed. Founded with a mission to eradicate cancer's mortality through early detection, the company has carved out a prominent niche with its flagship product, Cologuard. This non-invasive, stool-based DNA screening test for colorectal cancer offers an alternative to traditional colonoscopy, making cancer screening more accessible and less intimidating. By capitalizing on advancements in genomics and leveraging sophisticated algorithmic analysis, Exact Sciences has managed to transform routine medical testing, garnering robust support from both physicians and patients. The test, approved by regulatory bodies and integrated into various insurance plans, forms the cornerstone of Exact Sciences’ revenue model, contributing significantly to its bottom line by combining upfront test fees with ongoing follow-up services. Beyond colorectal cancer, Exact Sciences is ambitiously expanding its portfolio through both internal research and strategic acquisitions. The company's vision extends to a comprehensive suite of diagnostic tools covering multiple cancer types, notably breast and liver cancer, reflecting its commitment to innovation and growth. Recent acquisitions, such as Thrive Earlier Detection and PreventionGenetics, have fortified its capabilities in early-stage cancer detection and genetic testing, positioning it well for future opportunities. This strategic expansion not only broadens its product base but also enhances recurring revenue streams through continued engagement with healthcare providers and patients. By intertwining cutting-edge science with a savvy commercial strategy, Exact Sciences is shaping the future of personalized medicine while steadily augmenting its financial health.

EXAS Intrinsic Value
43.17 USD
Overvaluation 26%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-8%
=
Net Income
-214m
/
Revenue
2.7B
What is the Net Margin of Exact Sciences Corp?

Based on Exact Sciences Corp's most recent financial statements, the company has Net Margin of -8%.